Assessment of Safety and Effectiveness in Treatment Management of Paroxysmal Atrial Fibrillation With the BWI Pulsed Field Ablation System With OMNYPULSE™ Catheter
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 353
- 试验地点
- 130
- 主要终点
- Number of Participants with Primary Adverse Events (PAEs)
研究概览
简要总结
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with symptomatic paroxysmal AF with:
- •At least two symptomatic AF episodes within last six months from enrollment
- •At least one electrocardiographically documented AF episode within twelve months prior to enrollment
- •Failed at least one Class I or Class III antiarrhythmic drug
- •Willing and capable to provide consent
- •Able and willing to comply with all pre-, post- and follow-up testing and requirements
排除标准
- •Previously diagnosed with persistent AF (greater than [>] 7 days in duration)
- •AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- •Previous surgical or catheter ablation for AF
- •Patients known to require ablation outside the PV ostia and outside the CTI region.
- •Documented severe dilatation of the left atrium (LAD>50 mm) antero-posterior diameter on imaging within 6 months prior to enrollment
- •Documented left atrium (LA) thrombus by imaging within 48 hours of the procedure
- •Documented severely compromised left ventricular ejection fraction (LVEF <40%) by imaging within 6 months prior to enrollment
- •Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
- •History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
- •Documented thromboembolic event (including transient ischemic attack or TIA) within the past 6 months
- •Previous Percutaneous Coronary Intervention (PCI)/ myocardial infarction [MI] within the past 2 months
- •Coronary Artery Bypass Grafting (CABG) surgery within the past 6 months
- •Valvular cardiac surgical/percutaneous procedure
- •Unstable angina within 6 months
- •Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
- •Significant pulmonary disease or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- •Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study
- •Prior diagnosis of pulmonary vein stenosis
- •Pre-existing hemi diaphragmatic paralysis
- •Acute illness, active systemic infection, or sepsis
- •Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
- •Severe mitral regurgitation
- •Presence of an implanted pacemaker or Implantable Cardioverter-Defibrillator (ICD) or other implanted metal cardiac device (other than coronary stents) that may interfere with the PF energy field)
- •Presence of a condition that precludes vascular access
- •Current enrollment in an investigational study evaluating another device or drug
- •Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation
- •Life expectancy less than 12 months
- •Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions for Use (IFU)
研究组 & 干预措施
Pulsed Field (PF) Ablation System
Participants with PAF will undergo pulsed field ablation procedure with the OMNYPULSE™ catheter in combination with TRUPULSE™ generator for PVI and to deliver pulsed field (PF) energy for treatment of atrial fibrillation. Study participants will be followed for 12 months after the study index procedure.
干预措施: OMNYPULSE™ Catheter with the TRUPULSE Generator (Device)
结局指标
主要结局
Number of Participants with Primary Adverse Events (PAEs)
时间窗: 7 days post-procedure
Number of participants with PAEs (within 7 days following the ablation procedure unless otherwise indicated) will be reported. PAEs will include the following adverse events: esophageal perforating complications (atrio-esophageal fistula, esophago-pericardial fistula), phrenic nerve paralysis (permanent), cardiac tamponade/perforation, pulmonary vein stenosis (PVS), device or procedure related death, stroke/cerebrovascular accident (CVA), major vascular access complication/bleeding, thromboembolism, myocardial infarction, transient ischemic attack (TIA), pericarditis, heart block, pulmonary edema (respiratory insufficiency) and vagal nerve injury/gastroparesis.
Number of Participants Reporting Freedom from Documented (Symptomatic and Asymptomatic) Atrial Tachyarrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL] of Unknown Origin) Episodes
时间窗: Day 91 to Day 365 post-procedure
Number of participants reporting freedom from documented (symptomatic and asymptomatic) atrial tachyarrhythmia (AF, AT, or AFL of unknown origin) episodes of \>= 30 seconds based on sponsor provided transtelephonic monitoring (TTM) or holter device or continuous on standard 12-lead electrocardiogram (ECG) data during the effectiveness evaluation period will be reported.
次要结局
- Change from Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score(Baseline, Month 12)